Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 0 imaging study of RYZ512 in metastatic clear cell renal cell carcinoma
PACTR202605495669702Phase 0Not yet recruiting
- Sponsor
- RayzeBio
- Start
- Jun 2026
- Countries
- 1
01
Overview
Phase 0, open-label, single-arm trial in clear cell renal cell carcinoma (ccRCC), sponsored by RayzeBio. Primary endpoints: Safety and adverse events, Visual assessment of uptake and 3 more. Planned start Jun 2026; status: not yet recruiting.
02
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on PACTR202605495669702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605495669702.